Therefore, a combination of anti-activin A and anti-CAF therapy may improve outcome in a manner similar to how the addition of a smoothened inhibitor against the hedgehog pathway significantly improves the tumor suppression effect of SB431542, which targets the TGF-β/Nodal/Activin pathways67. The gene discussed is TGFB1; the disease is neoplasm.